Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

10 Mar 2010 07:00

RNS Number : 2903I
ViaLogy PLC
10 March 2010
 



VIALOGY PLC ("VIALOGY")

VIALOGY SIGNS RENEWABLE ENERGY CONTRACT WITH ENEL NORTH AMERICA TO CHARACTERIZE AND DE-RISK GEOTHERMAL PROSPECTS

n ViaLogy technology extended to green energy

n Goal is reduction of exploration/drilling risks/costs

 

London, March 10. ViaLogy (LSE:VIY) announces signing of a contract with Enel North America, a subsidiary of Enel Green Power, the Enel Group company operating renewable energy sources in 14 countries, including the US. Enel Green Power is one of the world's leading players in the renewables industry and a global leader in geothermal power generation. The Enel Group is Italy's largest power company and Europe's second listed utility by installed capacity.

Under its initial contract, ViaLogy will extend its QuantumRD sub-surface detection technology to seismic survey design, and the identification and location of appropriate geothermal drilling locations at an Enel North America site in Nevada.

Geothermal energy generation obliges commitment of very large capital resources, and a determining factor in the geothermal business equation is the inordinately high cost of exploration, drilling and extraction which entails significant risk. Geothermal well positioning requires robust detection and characterization of natural cracks and fractures in volcanic regions with extremely hard rock; accurate mapping of fractures and discontinuities forming pressurized traps; and mapping formations that can support drilling holes with large diameters in hard rock.

QuantumRD's ability to assess complex subsurface stratigraphy, porosity and fluid saturation levels more accurately than other current technologies, utilizing seismic, magneto-telluric and other chemical tracer data, should reduce risk and alter the sector's investment risk profile. Over time, this could contribute to the broader use of clean, environmentally sustainable geothermal-based electricity.

ViaLogy's Energy business focus remains squarely on the upstream hydrocarbon industry sector where its QuantumRD technology is projected to build upon its success thus far to become an industry standard. But the opportunity to bring its technology to bear in such a vital and financially promising part of the green energy industry is important to the company's future success and earnings, as well as an opportunity to do its part in mitigating the effects of global warming.

ViaLogy CEO, Robert W. Dean, said, "The Enel contract opens up a new market for us in renewable energy development. It broadens our business base, and provides yet another means of developing and refining our QuantumRD technology, and could be a significant source of 'green' growth."

 

 

For further information please contact

ViaLogy plc

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley +44 (0) 20-7107-8000

 

 

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com. Except for statements of historical fact, the information presented herein constitutes forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results.

 

About Enel Green Power and Enel North America

Enel Green Power is the renewable power company of Enel S.p.A. aimed at developing and operating power generation from renewable sources in Italy and around the world. The company's business incorporates all of Enel's activities in the wind, solar, geothermal, hydroelectric and biomass fields in Europe, North America and Central and South America. With over 4,500 MW of installed capacity and 17.2 TWh of produced electricity in 2008, Enel Green Power is a leading global company in renewables. Enel North America, Inc. is a subsidiary of Enel Green Power and operates all EGP renewable energy plants in 20 U.S. States and in three Canadian Provinces. For further information, please visit http://enelgreenpower.com/en/.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTSSDFSUFSSEED
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.